Corporate Profile:
The following overview reflects HTTD’s strategy in order to achieve its goals. The information contained in this websites “Corporate Overview” and “Presentation Regarding The Use Of Tubercin®” flash presentations has been outdated for quite a while. HTTD will revise and update this website when resources are available, ideally in the near future.
As an emerging biotech company, Hard to Treat Diseases, Inc. (“HTTD”) is focused on developing its marketing and licensing rights, proprietary formulation and other compounds and substances with aggressive testing that has and is currently being conducted in U.S. FDA approved laboratories. HTTD’s goal is to have its biotech assets, including testing results, positioned for acquisition by a major pharmaceutical firm within 18 months. HTTD envisions its products being utilized worldwide as soon as possible.
The corporate headquarters for HTTD is in Delray Beach, Florida and all testing is conducted at institutions located in the U.S. that are FDA approved.
HTTD’s strategy is not to become a drug firm and not to compete with the drug firms. HTTD has no desire to manufacture or market products outside the U.S., notwithstanding the overseas success of Tubercin® in South Korea. The majority of successful drugs on the market are acquired by major drug firms from biotech companies. HTTD will not conduct Phase III clinical trials related to FDA approval. The major drug company that acquires HTTD’s assets will have the resources to gain FDA approval and decide if FDA “fast track” approval is possible. In addition, the acquiring company will obviously have the infrastructure to manufacture, market and distribute HTTD’s products globally and the resources to assure rapid development.
Manufacturing and distribution are not part of HTTD’s plans. HTTD’s business model reflects having its biotech assets acquired by a major drug company. This transaction will achieve the goal of benefiting HTTD’s shareholders and the drug company will be responsible for achieving the goal of benefiting patients.
In December 2004 HTTD filed a U.S. Provisional Patent Application for Methods and Compositions for Treatment of Viral Infections. The provisional application discloses the testing results of HTTD’s proprietary formulation for the treatment of viral infections, which was filed on behalf of HTTD as a result of ongoing testing and research conducted on various compounds and substances that HTTD owns, controls or has the licensed rights to. Testing results could not be released until the provisional application was filed due to the confidential and sensitive nature of the information.
Testing results to date have been finalized and incorporated in the provisional application. An overview of the results will be released in the very near future. The testing documents comprise a valuable asset that has been created for HTTD. This asset, along with the underlying testing documents, is confidential, not available to competitors, and HTTD has taken extraordinary steps to maintain its confidential nature and contents.
HTTD is no longer a “one-drug company” that is reliant solely on the promotion of Tubercin®. In addition to the companies proprietary formulation and various compounds, referenced in the provisional application, HTTD also acquired and holds the worldwide (except Korea) marketing rights and license to manufacture, use, market, distribute and otherwise to commercialize Tubercin®, which includes Tubercin®’s issued patents in the following countries:
Japanese patent: issued 6/12/98
United States patent: issued 8/14/01
European patent: issued 8/13/03
Canada patent: issued 5/11/04
HTTD’s value and goals have been strengthened with the provisional application. HTTD will continue to aggressively advance the testing of Tubercin® in the U.S.; in addition to aggressively advance the testing of its proprietary formulation and other compounds and substances, contained in the provisional application, in the U.S.; and make strategic decisions with the goal of being involved in negotiations with major drug firms within 18 months.
Testing and evaluation results are an essential interim step in obtaining the FDA approval necessary to market a product. HTTD’s testing and research has been supervised and conducted in U.S. FDA approved laboratories by experienced medical and scientific professionals. HTTD will vigorously enforce its lawful rights, which includes defending its advantageous business relationships and negotiations that are instrumental in establishing a solid reputation and significant presence in our field and attaining the goals of benefiting patients and HTTD’s shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin®. Additional information and details regarding the litigation can be viewed on this websites homepage by clicking on the top captions and by reviewing the press releases listed in the News section.
TUBERCIN®
Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients has been rising in the U.S., Europe, Japan, China and Korea. The decisive measure to cope with cancer is surgery. When cancer cells spread throughout the body, instead of remaining on the original spot, the treatment should take chemotherapy, radiation therapy and immunotherapy into consideration. The drawback of such therapies, however, is that they incur damage not only to cancer cells, but also on the normal cells. Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short in therapeutic expectation. When Bacille calmettequerin is used as an active non-specific immunotherapeutic agent, the patients’ prognosis becomes better through a simulative action on the immune system of the cancer case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin® from micro bacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphokine. This process strengthened and promoted immuno surveillance activities in the deficient state and alleviated pain and prolonged the life of cancer patients. Pharmaceutical companies in advanced countries have recently marketed cancer vaccines (active specific immunotherapy). The vaccines, bacterial extracts, as adjuvant, with autoogous and or allogenic cancer cells to generate antibodies to cancer cells, facilitate the killer T- cells to recognize and destroy cancer cells.
Tubercin® is derived from micro bacterium tuberculosis. As an immunostimulant, Tubercin® strengthens the human body’s own immune system and assists the body in seeking out and combating cancer cells. HTTD’s goal is for a major drug firm to develop Tubercin® into a low cost product to treat cancer patients on an international scale. Salient treatment through the administration of Tubercin® could positively affect thousands of lives in North America. In addition, Europe and Asia have millions of lives at risk each year because of diseases such as cancer.
. |
